Lewis Silverman
Overview
Explore the profile of Lewis Silverman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pelland-Marcotte M, Belaktib A, Droit A, Remy M, Clement J, Bianco S, et al.
J Thromb Haemost
. 2024 Dec;
23(3):1009-1022.
PMID: 39694444
Background: Venous thromboembolism (VTE) is a frequent complication of childhood acute lymphoblastic leukemia (ALL). Objectives: We aimed to identify molecular markers and signatures of the leukemia microenvironment associated with VTE...
2.
Sango J, Carcamo S, Sirenko M, Maiti A, Mansour H, Ulukaya G, et al.
Nature
. 2024 Oct;
636(8041):241-250.
PMID: 39478230
Cancer driver mutations often show distinct temporal acquisition patterns, but the biological basis for this, if any, remains unknown. RAS mutations occur invariably late in the course of acute myeloid...
3.
Balev M, Zibara V, Van Hyfte G, Feld J, Kremyanskaya M, Becker M, et al.
Am J Hematol
. 2024 Jul;
99(10):2026-2028.
PMID: 38970273
Multivariable analysis for overall survival and relapse-free survival demonstrating lack of significant for D14 BM status.
4.
Wheeler E, Vora S, Mayer D, Kotini A, Olszewska M, Park S, et al.
Cancer Discov
. 2021 Oct;
12(3):836-855.
PMID: 34620690
Significance: SF mutations are disease-defining in MDS, but their critical effectors remain unknown. We discover the first direct target of convergent missplicing by mutant U2AF1 and SRSF2, a long GNAS...
5.
Baruchel A, Brown P, Rizzari C, Silverman L, Van der Sluis I, Wolthers B, et al.
ESMO Open
. 2020 Sep;
5(5):e000977.
PMID: 32967920
Insufficient exposure to asparaginase therapy is a barrier to optimal treatment and survival in childhood acute lymphoblastic leukaemia (ALL). Three important reasons for inactivity or discontinuation of asparaginase therapy are...
6.
Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, et al.
J Natl Compr Canc Netw
. 2020 Jan;
18(1):81-112.
PMID: 31910389
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have...
7.
Rae C, Furlong W, Feeny D, Couchman R, Silverman L, Sallan S, et al.
J Pediatr Hematol Oncol
. 2018 Jun;
40(8):580-587.
PMID: 29901560
Health-related quality of life (HRQL) improved progressively during therapy and beyond in children treated for acute lymphoblastic leukemia on the Dana-Farber Cancer Institute (DFCI) 95-01 protocol. This study aimed to...
8.
Kotini A, Chang C, Chow A, Yuan H, Ho T, Wang T, et al.
Cell Stem Cell
. 2017 Feb;
20(3):315-328.e7.
PMID: 28215825
Myeloid malignancy is increasingly viewed as a disease spectrum, comprising hematopoietic disorders that extend across a phenotypic continuum ranging from clonal hematopoiesis to myelodysplastic syndrome (MDS) and acute myeloid leukemia...
9.
Dabscheck G, Silverman L, Ullrich N
J Pediatr Hematol Oncol
. 2015 Aug;
37(7):568-9.
PMID: 26274034
A 5-year-old boy with standard-risk B-cell acute lymphoblastic anemia developed fever during induction chemotherapy. The patient had no neurological symptoms. Blood cultures grew Bacillus cereus and neuroimaging studies demonstrated a...
10.
Ohnuma T, Lehrer D, Ren C, Cho S, Maniar M, Silverman L, et al.
Am J Cancer Res
. 2013 Jul;
3(3):323-38.
PMID: 23841031
Rigosertib (ON 01910.Na), a synthetic novel benzyl styryl sulfone, was administered to 28 patients with advanced cancer in a Phase I trial in order to characterize its pharmacokinetic profile, determine...